PACTR201510001143243招募中未知
A randomized phase 11a trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi's sarcomain patients on combination antiretroviral therapy in western kenya
AMPATH Oncology Institute0 个研究点目标入组 70 人开始时间: 2015年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 90 Year(s)（—）
- 性别
- All
入选标准
- •Histologically confirmed Kaposi's sarcoma
- •Documented HIV positive state
- •Documented CD4 cell count
- •Signed informed consent form
- •Stage T0 should have taken ARVs for at least 8 weeks
- •Age over 18 years
- •Adequate hematologic function i.e neutrophil count more than 1000/microliter of bllod,plateles more than 75000 and HB more tha 10grams
- •Creatinine level less tha 200mocrograms per ml of blood
- •ECOG score less than 2
- •Negative pregnancy test with dual contraception for women of reproductive age
排除标准
- •Previous treatment with chemotherapy or radiotherapy
- •Unmeasurable KS lesions
- •Concurrent febrile illneses
- •Concurrent malignancy
- •Allergic reaction to any of the study drugs
- •Breast feeding
研究者
相似试验
已完成
2 期
A randomised phase II trial comparing gemcitabine vs TS-1 in patients with resected pancreatic cancerJPRN-UMIN000003544Dokkyo Medical University Hospital60
已完成
2 期
Randomized phase II study comparing Gemcitabine chemoradiotherapy with Gemcitabine chemotherapy for unresectable locally advanced pancreatic cancer.nresectable locally advanced pancreatic cancer.JPRN-UMIN000012253Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology110
进行中（未招募）
1 期
Full-dose single-agent chemotherapy (gemcitabine) or reduced-dose combination chemotherapy as first palliative treatment for fragile patients with advanced pancreatic cancer.Pancreatic CancerEUCTR2021-005067-52-DKAalborg University Hospital, Department of Oncology100
已完成
2 期
Randomized phase II study comparing Gemcitabine versus TS-1 for advanced bile duct cancerAdvanced bile duct cancerJPRN-UMIN000001595Osaka International Cancer Institute Department of Hepatobiliary and pancreatic Oncology110
进行中（未招募）
不适用
Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head cancerEUCTR2005-000933-39-DEEuropean Organisation for Research and Treatment of Cancer538